Literature DB >> 23850656

Controlling herpetic stromal keratitis by modulating lymphotoxin-alpha-mediated inflammatory pathways.

Tamara Veiga-Parga1, Fernanda Giménez, Sachin Mulik, Eugene Y Chiang, Jane L Grogan, Barry T Rouse.   

Abstract

Herpes simplex virus 1 infection of the eye can result in stromal keratitis, a chronic immunoinflammatory lesion that is a significant cause of human blindness. A key to controlling the severity of lesions is to identify cellular and molecular events responsible for tissue damage. This report evaluates the role of lymphotoxin-α, a proinflammatory cytokine that could be involved during stromal keratitis. We demonstrate that after infection, both lymphotoxin-α and lymphotoxin-β transcripts are detectable at high levels 48 h postinfection, suggesting roles for the secreted homotrimer lymphotoxin-α3 and the membrane-bound lymphotoxin-α1β2 heterotrimer in stromal keratitis. Using a corneal stromal fibroblast cell line, lymphotoxin-α3 and lymphotoxin-α1β2 were found to have proinflammatory roles by stimulating production of chemokines. Treatment of mice with a depleting anti-lymphotoxin-α mAb during the clinical phase of the disease significantly attenuated stromal keratitis lesions. In treated mice, expression of proinflammatory molecules and chemokines was reduced, as were numbers of cornea-infiltrating proinflammatory cells, particularly Th1 cells. The protective effect of anti-lymphotoxin-α mAb was highly reduced with a mutant version of the mAb that lacks Fc receptor binding activity, indicating that depletion of lymphotoxin-expressing cells was mainly responsible for efficacy, with LT-α3 contributing minimally to inflammation. These data demonstrate that lymphotoxin-expressing cells, such as Th1 cells, mediate stromal keratitis.
Copyright © 2013 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CD4(+) T cells; HSV-1; Lymphotoxin alpha; SK; Th1

Mesh:

Substances:

Year:  2013        PMID: 23850656      PMCID: PMC3769451          DOI: 10.1016/j.micinf.2013.07.001

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  31 in total

1.  High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Authors:  R L Shields; A K Namenuk; K Hong; Y G Meng; J Rae; J Briggs; D Xie; J Lai; A Stadlen; B Li; J A Fox; L G Presta
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

Review 2.  Lymphotoxin/light, lymphoid microenvironments and autoimmune disease.

Authors:  Jennifer L Gommerman; Jeffrey L Browning
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

3.  Pathogenesis of herpetic encephalitis in mice after ophthalmic inoculation.

Authors:  F B Knotts; M L Cook; J G Stevens
Journal:  J Infect Dis       Date:  1974-07       Impact factor: 5.226

Review 4.  Pathogenesis of herpes stromal keratitis--a focus on corneal neovascularization.

Authors:  Fernanda Giménez; Amol Suryawanshi; Barry T Rouse
Journal:  Prog Retin Eye Res       Date:  2012-08-07       Impact factor: 21.198

5.  Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis.

Authors:  M G Niemialtowski; B T Rouse
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

6.  Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis.

Authors:  R G Russell; M P Nasisse; H S Larsen; B T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  1984-08       Impact factor: 4.799

7.  IFN-gamma and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice.

Authors:  R L Hendricks; T M Tumpey; A Finnegan
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

8.  Herpes simplex eye infections: clinical manifestations, pathogenesis and management.

Authors:  C R Dawson; B Togni
Journal:  Surv Ophthalmol       Date:  1976 Sep-Oct       Impact factor: 6.048

9.  Herpetic stromal keratitis-evidence for cell-mediated immunopathogenesis.

Authors:  J F Metcalf; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1976-12       Impact factor: 5.258

Review 10.  Herpetic eye disease: immunopathogenesis and therapeutic measures.

Authors:  Shilpa Deshpande; Kaustuv Banerjee; Partha Sarathi Biswas; Barry T Rouse
Journal:  Expert Rev Mol Med       Date:  2004-03-30       Impact factor: 5.600

View more
  6 in total

Review 1.  Ocular diseases: immunological and molecular mechanisms.

Authors:  Jing Song; Yi-Fei Huang; Wen-Jing Zhang; Xiao-Fei Chen; Yu-Mian Guo
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 2.  Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation.

Authors:  Ann-Marie Lobo; Alex M Agelidis; Deepak Shukla
Journal:  Ocul Surf       Date:  2018-10-11       Impact factor: 5.033

Review 3.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

4.  A forward phenotypically driven unbiased genetic analysis of host genes that moderate herpes simplex virus virulence and stromal keratitis in mice.

Authors:  Richard L Thompson; Robert W Williams; Malak Kotb; Nancy M Sawtell
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

5.  Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod.

Authors:  Maryam Nakhaei-Nejad; David Barilla; Chieh-Hsin Lee; Gregg Blevins; Fabrizio Giuliani
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-12-28

Review 6.  Understanding the Role of Chemokines and Cytokines in Experimental Models of Herpes Simplex Keratitis.

Authors:  Tayaba N Azher; Xiao-Tang Yin; Patrick M Stuart
Journal:  J Immunol Res       Date:  2017-04-09       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.